Human kallikrein 8: Immunoassay development and identification in tissue extracts and biological fluids

Clinical Chemistry

Volumn 49, Issue 1, 2003, Pages 87-96

  Kishi, Tadaaki ^a,b   Grass, Linda ^a   Soosaipillai, Antoninus ^a   Shimizu Okabe, Chigusa ^c   Diamandis, Eleftherios P ^a,b  

^a MOUNT SINAI HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

KALLIKREIN; NEUROPSIN; STEROID HORMONE; TUMOR MARKER; UNCLASSIFIED DRUG;

AMNION FLUID; ARTICLE; BACULOVIRUS; BODY FLUID; BREAST; BREAST MILK; CHROMATOGRAPHY; CROSS REACTION; ENZYME IMMUNOASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; ESOPHAGUS; HUMAN; IMMUNOASSAY; KIDNEY; PREDICTION; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN PURIFICATION; PROTEIN SECRETION; SALIVARY GLAND; SEMINAL PLASMA; SENSITIVITY AND SPECIFICITY; SKIN; TESTIS; TISSUE SPECIFICITY; TONSIL;

ADULT; ANIMALS; ANTIBODIES; BACULOVIRIDAE; BIOLOGICAL MARKERS; BODY FLUIDS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; ELECTROPHORESIS, POLYACRYLAMIDE GEL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HORMONES; HUMANS; KALLIKREINS; MALE; MICE; MICE, INBRED BALB C; MIDDLE AGED; RABBITS; RECOMBINANT PROTEINS; SENSITIVITY AND SPECIFICITY; TISSUE EXTRACTS; TUMOR CELLS, CULTURED;

ORYCTOLAGUS CUNICULUS; UNIDENTIFIED BACULOVIRUS;

EID: 0037230511     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1373/49.1.87     Document Type: Article

References (30)

1. Diamandis EP, Yousef GM, Luo LY, Magklara A, Obiezu CV. The new human kallikrein gene family: implications in carcinogenesis. Trends Endocrinol Metab 2000;11:54-60.
2. Yousef GM, Diamandis EP. The new human tissue kallikrein gene family: structure, function, and association to disease. Endocr Rev 2001;22:184-204.
3. Barry MJ. Clinical practice, prostate-specific antigen testing for early diagnosis of prostate cancer. N Engl J Med 2001;344:1373-7.
4. Diamandis EP, Yousef GM, Soosaipillai AR, Bunting P. Human kallikrein 6 (zyme/protease M/neurosin): a new serum biomarker of ovarian carcinoma. Clin Biochem 2000;33:579-83.
5. Luo LY, Bunting P, Scorilas A, Diamandis EP. Human kallikrein 10: a novel tumor marker for ovarian carcinoma? Clin Chim Acta 2001;306:111-8.
6. Diamandis EP, Okui A, Mitsui S, Luo LY, Soosaipillai A, Grass L, et al. Human kallikrein 11: a new biomarker of prostate and ovarian carcinoma. Cancer Res 2002;62:295-300.
7. Diamandis EP, Yousef GM. Human tissue kallikrein gene family: a rich source of novel disease biomarkers. Expert Rev Mol Diagn 2001;1:182-90.
8. Diamandis EP, Yousef GM, Clements J, Ashworth LK, Yoshida S, Egelrud T, et al. New nomenclature for the human tissue kallikrein gene family. Clin Chem 2000;46:1855-8.
9. Yoshida S, Taniguchi M, Hirata A, Shiosaka S. Sequence analysis and expression of human neuropsin cDNA and gene. Gene 1998; 213:9-16.
10. Chen ZL, Yoshida S, Kato K, Momota Y, Suzuki J, Tanaka T, et al. Expression and activity-dependent changes of a novel limbic-serine protease gene in the hippocampus. J Neurosci 1995;15:5088-97.
11. Okabe A, Momota Y, Yoshida S, Hirata A, Ito J, Nishino H, et al. Kindling induces neuropsin mRNA in the mouse brain. Brain Res 1996;728:116-20.
12. Momota Y, Yoshida S, Ito J, Shibata M, Kato K, Sakurai K, et al. Blockade of neuropsin, a serine protease, ameliorates kindling epilepsy. Eur J Neurosci 1998;10:760-4.
13. Komai S, Matsuyama T, Matsumoto K, Kato K, Kobayashi M, Imamura K, et al. Neuropsin regulates an early phase of Schaffer-collateral long-term potentiation in the murine hippocampus. Eur J Neurosci 2000;12:1479-86.
14. Shimizu-Okabe C, Yousef GM, Diamandis EP, Yoshida S, Shiosaka S, Fahnestock M. Expression of the kallikrein gene family in normal and Alzheimer's disease brain. Neuroreport 2001;12:2747-51.
15. Underwood LJ, Tanimoto H, Wang Y, Shigemasa K, Parmley TH, O'Brien TJ. Cloning of tumor-associated differentially expressed gene-14, a novel serine protease overexpressed by ovarian carcinoma. Cancer Res 1999;59:4435-9.
16. Magklara A, Scorilas A, Katsaros D, Massobrio M, Yousef GM, Fracchioli S, et al. The human KLK8 (neuropsin/ovasin) gene: identification of two novel splice variants and its prognostic value in ovarian cancer. Clin Cancer Res 2001;7:806-11.
17. Mitsui S, Tsuruoka N, Yamashiro K, Nakazato H, Yamaguchi N. A novel form of human neuropsin, a brain-related serine protease, is generated by alternative splicing and is expressed preferentially in human adult brain. Eur J Biochem 1999;260:627-34.
18. Luo LY, Grass L, Howarth DJ, Thibault P, Ong H, Diamandis EP. Immunofluorometric assay of human kallikrein 10 and its identification in biological fluids and tissues. Clin Chem 2001;47:237-46.
19. Christopoulos TK, Diamandis EP. Enzymatically amplified time-resolved fluorescence immunoassay with terbium chelates. Anal Chem 1992;64:342-6.
20. Yu H, Diamandis EP. Ultrasensitive time-resolved immunofluorometric assay of prostate-specific antigen in serum and preliminary clinical studies. Clin Chem 1993;39:2108-14.
21. Shimizu C, Yoshida S, Shibata M, Kato K, Momota Y, Matsumoto K, et al. Characterization of recombinant and brain neuropsin, a plasticity-related serine protease. J Biol Chem 1998;273:11189-96.
22. Diamandis EP, Yousef GM, Soosaipillai AR, Grass L, Porter A, Little S, et al. Immunofluorometric assay of human kallikrein 6 (zyme/protease M/neurosin) and preliminary clinical applications. Clin Biochem 2000;33:369-75.
23. Petraki CD, Karavana VN, Skoufogiannis PT, Little SP, Howarth DJ, Yousef GM, et al. The spectrum of human kallikrein 6 (zyme/protease M/neurosin) expression in human tissues as assessed by immunohistochemistry. J Histochem Cytochem 2001;49:1431-42.
24. Cleutjens KB, van der Korput HA, van Eekelen CC, van Rooij HC, Faber PW, Trapman J. An androgen response element in a far upstream enhancer region is essential for high, androgen-regulated activity of the prostate-specific antigen promoter. Mol Endocrinol 1997;11:148-61.
25. Xie X, Zhao X, Liu Y, Young CY, Tindall DJ, Slawin KM, et al. Robust prostate-specific expression for targeted gene therapy based on the human kallikrein 2 promoter. Hum Gene Ther 2001;12:549-61.
26. Christensson A, Laurell CB, Lilja H. Enzymatic activity of prostate-specific antigen and its reactions with extracellular serine proteinase inhibitors. Eur J Biochem 1990;194:755-63.
27. Stenman UH, Leinonen J, Alfthan H, Rannikko S, Tuhkanen K, Alfthan O. A complex between prostate-specific antigen and α1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer. Cancer Res 1991;51:222-6.
28. Stephan C, Jung K, Lein M, Sinha P, Schnorr D, Loening SA. Molecular forms of prostate-specific antigen and human kallikrein 2 as promising tools for early diagnosis of prostate cancer. Cancer Epidemiol Biomarkera Prev 2000;9:1133-47.
29. Saedi MS, Zhu Z, Marker K, Liu RS, Carpenter PM, Rittenhouse H, et al. Human kallikrein 2 (hK2), but not prostate-specific antigen (PSA), rapidly complexes with protease inhibitor 6 (Pl-6) released from prostate carcinoma cells. Int J Cancer 2001;94:558-63.
30. Ferguson RA, Yu H, Kalyvas M, Zammit S, Diamandis EP. Ultra-sensitive detection of prostate specific antigen by a time-resolved immunofluorometric assay and the Immulite® Immunochemiluminescent third generation assay: potential applications in prostate and breast cancers. Clin Chem 1996;42:675-84.